Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

NovaBay Pharmaceuticals (NBY) Receivables - Net (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Receivables - Net for 15 consecutive years, with $368000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables - Net fell 47.73% to $368000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $368000.0, a 47.73% decrease, with the full-year FY2023 number at $680000.0, down 65.53% from a year prior.
  • Receivables - Net was $368000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $704000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $2.6 million in Q2 2023 to a low of $200000.0 in Q1 2022.
  • A 5-year average of $1.2 million and a median of $977000.0 in 2021 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: plummeted 80.73% in 2022, then soared 817.5% in 2023.
  • NovaBay Pharmaceuticals' Receivables - Net stood at $1.7 million in 2021, then rose by 18.29% to $2.0 million in 2022, then plummeted by 65.53% to $680000.0 in 2023, then grew by 3.53% to $704000.0 in 2024, then plummeted by 47.73% to $368000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Receivables - Net are $368000.0 (Q3 2025), $704000.0 (Q3 2024), and $547000.0 (Q2 2024).